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We report a case of ciprofloxacin treatment failure in a
typhoid fever patient at a tertiary care hospital in
Rawalpindi, Pakistan. This case shows not only the emer-
gence of fluoroquinolone resistance in typhoid salmonellae
but also the inadequacy of the current laboratory guidelines
for detection of this resistance.
T
yphoid fever is a major health concern in the develop-
ing world; >16 million new cases occur worldwide
annually, resulting in approximately 600,000 deaths per
year. The last two decades have seen the emergence and
spread of multidrug resistance against the conventional
antityphoid drugs (chloramphenicol, co-trimoxazole, and
ampicillin) among the typhoid salmonellae, especially in
South and Southeast Asia, including Pakistan. These
developments had left fluoroquinolones as the antimicro-
bial agents of choice for the treatment of typhoid fever (1).
Fluoroquinolone resistance is being reported with increas-
ing frequency from all over the world (1–5). We report
ciprofloxacin treatment failure in a case of typhoid fever.
Case Report
Apreviously healthy 14-year-old boy from Rawalpindi,
Pakistan, was admitted in July 2002 to Combined Military
Hospital, Rawalpindi, with a 7-day history of a high fever
(>38°C) and vomiting. He had relative bradycardia (heart
rate 84 bpm) and a soft palpable spleen. His total leukocyte
count was 3 x 109/L. Malarial parasites were not seen on
examination of thin and thick smears of peripheral blood.
The results of a routine urinalysis and chest radiographs
were normal. A blood Widal test showed a titer of 320
against “O” (somatic) antigen of Salmonella enterica
serovar Typhi. Blood culture yielded the growth of
Salmonella Typhi. The isolate was found to be resistant to
the conventional antityphoid drugs by using modified
Kirby-Bauer disk diffusion technique according to the cri-
teria of the National Committee for Clinical Laboratory
Standards (NCCLS) (6). The disks of antimicrobial drugs
used were chloramphenicol (30 µg), co-trimoxazole
(1.25/23.75 µg), ampicillin (10 µg), ciprofloxacin (5 µg),
and ceftriaxone (30 µg). The isolate appeared susceptible
to ciprofloxacin and ceftriaxone. 
The patient was given ciprofloxacin, 500 mg, every 12
hours, orally, on admission but remained febrile after 3
days of treatment. When the blood culture report was
received, and in view of the susceptibility pattern, intra-
venous ciprofloxacin, 200 mg every 12 hours, was admin-
istered. Despite 8 days of treatment, his fever did not
resolve. The isolate was reviewed and the MIC of
ciprofloxacin was determined by Kirby-Bauer broth dilu-
tion technique; it was 0.5 µg/mL; well below the NCCLS
recommended break point value of 1 µg/mL (7). However,
in light of the treatment failure with ciprofloxacin, intra-
venous ceftriaxone, 1 g every 12 hours, was administered,
and the patient responded within 3 days.
Conclusions
This case highlights two developments: first, the
increasing incidence of reduced susceptibility and resist-
ance of typhoid salmonellae against fluoroquinolones, and
second, the inadequacy of the present laboratory guide-
lines for detecting fluoroquinolone resistance in typhoid
salmonellae. The first case of ciprofloxacin-resistant
typhoid fever was reported in 1992 in the United Kingdom
(8), and the first case of fluoroquinolone treatment failure
in typhoid fever in Pakistan was reported in 1993 (9).
Similar cases have been reported from several other coun-
tries (1–5). Selective pressure on the bacterial population
by uncontrolled use of these antimicrobial drugs has likely
led to the emergence of this resistance (2),which has been
attributed to a single point mutation in the quinolone-
resistance–determining region (QRDR) of the topoiso-
merase gene gyrA (1,2,5,10). However,other mechanisms
such as decreased permeability and active efflux of the
antimicrobial agent may also be involved (10).
The inadequacy of the current in vitro antimicrobial
susceptibility testing for detecting fluoroquinolone treat-
ment failure in typhoid fever is apparent in this case.
According to NCCLS guidelines, Enterobacteriaceae
(including typhoid salmonellae) are susceptible to the MIC
of <1 µg/mL of ciprofloxacin, while resistant to the MIC
of >4 µg/mL (7). But in our case-patient, treatment failed,
even though the MIC was stated as 0.5 µg/mL. Similar
observations have been made in other countries (2–5,11).
Keeping in view this absence of correlation between MIC
of fluoroquinolones and therapeutic response in typhoid
fever,  we recommended break point MIC values of
ciprofloxacin in cases of typhoid salmonellae infection as
follows: <0.125 µg/mL as susceptible, 0.125 µg/mL–
1 µg/mL as reduced susceptibility, and >1 µg/mL as resist-
ant. Determination of MIC may not be practicable in rou-
tine laboratory practice, particularly outside of a reference
laboratory in developing countries. Also, disk diffusion
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these new recommended MICs, and detecting mutation in
the QRDR of gyrA gene by polymerase chain reaction
(PCR) would not be practical or cost-effective. Several
authors have reported a correlation between resistance to
nalidixic acid and reduced susceptibility to ciprofloxacin
and other fluoroquinolones (2,11). Routine testing of
resistance to nalidixic acid with a disk content of 30 µg can
serve as a useful screening test for fluoroquinolone resist-
ance (11). However, revision of the diagnostic criteria for
detecting fluoroquinolone resistance in typhoid salmonel-
lae is needed, particularly to validate clinically all the lab-
oratory-based anecdotal studies. Even with adoption of the
new recommended MICs of fluoroquinolones against
typhoid salmonellae, MICs would have to be correlated
with inhibition zone size by disk diffusion technique and
the clinical response in infection with typhoid salmonellae
depicting reduced susceptibility against quinolones.
To summarize, fluoroquinolones are the most effective
antimicrobial agents for treating enteric fevers (1).
Emergence of resistance against them is of major concern.
The spread of this resistance would leave only the less
effective (1,2), but more expensive, third-generation
cephalosporins for treatment of typhoid. Fluoroquinolone
resistance must be identified early, and these drugs must be
used judiciously. Otherwise, society may be faced with the
prospect of untreatable typhoid fever.
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